Adaptimmune Reports Q1 Financial Results and Provides Business Update
TECELRA®launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced
$4.0 million Tecelra net sales in Q1 2025
Instituting 2025 Tecelra full year sales guidance of $35-$45 million
Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026
Adaptimmune hadTotal Liquidity1of $60 million as of March 31, 2025;call at 8 a.m. EDT today
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March 31, 2025.
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: 'The launch of Tecelra continues to rapidly accelerate, as evidenced by all launch metrics. In Q4 2024 we invoiced 2 patients, in Q1 2025 we invoiced 6 patients, and in Q2 to-date we have invoiced 8 patients. The shape of the pipeline of patients being tested and apheresed continues to support a robust acceleration of sales in Q2 and the second half of the year, and we continue to experience 100% manufacturing success rates and no payer denials. As a result, we are now providing guidance for 2025 Tecelra sales in the range of $35-$45 million. I'm confident in the team's ability to identify eligible patients, manufacture a personalized engineered T cell treatment and ultimately deliver product, demonstrating that we have built a successful business platform for cell therapies in solid tumors, paving the way for an equally successful lete-cel launch in 2026.'
Tecelra launch momentum increasing - first commercial product in Adaptimmune's sarcoma franchise
Lete-cel - next product in Adaptimmune's sarcoma franchise
Corporate updates
Upcoming milestones
Financial Results for the three months ended March 31, 2025
Going Concern
Our 2024 Annual Report on Form 10-K, which the Company filed on March 24, 2025, disclosed that there is substantial doubt about our ability to continue as a going concern. We are continuing to implement cost reduction measures and explore the strategic options outlined above.
Today's Webcast Details
A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
About Adaptimmune
Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.
Forward-Looking Statements
This release contains 'forward-looking statements' within the meaning of the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as 'anticipate' 'believe,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Total Liquidity (a non-GAAP financial measure)
Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the condensed consolidated balance sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the condensed consolidated financial statements, which reconciles to Total Liquidity as follows (in thousands):
[This table cannot be displayed. Please visit the source.]
The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall solvency and liquidity, financial flexibility, capital position and leverage.
Condensed Consolidated Statement of Operations
(unaudited, in thousands, except per share data)
[This table cannot be displayed. Please visit the source.]
Condensed Consolidated Balance Sheets
(unaudited, in thousands, except share data)
[This table cannot be displayed. Please visit the source.]
Condensed Consolidated Cash Flow Statement
(unaudited, in thousands)
[This table cannot be displayed. Please visit the source.]
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
[email protected]
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
[email protected]
1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below
2 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251851
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
12 minutes ago
- New York Times
Las Vegas agrees two-year Formula One contract extension through 2027
MONTREAL — The Las Vegas Grand Prix will remain part of the Formula One calendar for at least the next two years after officials confirmed they have agreed an extension to cover 2026 and 2027. Las Vegas joined the F1 calendar in 2023 on an initial three-year contract, albeit with a long-term commitment in place from the casino partners and a 10-year approval from Clark County for the race to take place along the Strip. Advertisement Earlier this week, F1 announced the 2026 calendar including Las Vegas despite there being no formal communication about the race being renewed beyond this year. Senior leadership members from casino partners including Wynn, the MGM Grand, Caesars and the Venetian, plus the Las Vegas Convention and Visitors Authority, were in Montreal on Saturday to take part in a media panel discussing the future of the Las Vegas Grand Prix, and referred to an 'extension' being in place. Asked by The Athletic to clarify the contractual status of the grand prix, Emily Prazer, the president of the Las Vegas Grand Prix and chief commercial officer of F1, confirmed that a two-year renewal had been agreed by the various partners. 'We've agreed collectively that we're going to do a two-year extension for 2026 and '27,' Prazer said. 'We want to make sure that we're continuing to evolve what we're doing. But the intent is a much longer-term arrangement. 'As we all know, the race has had its challenges, but we're coming out the other side. So we want to make sure that it continues to work for both sides. 'So collectively, we sat down and agreed that was the best approach. We're very much planning longer-term, but that's kind of where we're at right now.' Steve Hill, the CEO and president of the LVCVA, added: 'The length of extensions don't really reflect anything other than it just makes sense incrementally, we know what's going to happen over the next couple of years. 'We're planning on this being a permanent race, we'll just keep planning extensions that will probably expand as we go forward.' The Las Vegas Grand Prix endured a tricky debut in 2023 amid concerns from fans about ticket and hotel prices, as well as an issue with a loose water valve cover on Thursday night in practice that led to FP1 being cancelled and FP2 being significantly delayed. Advertisement But it ended up being one of the best races of the year with plenty of overtaking, and the track layout proved popular with the drivers, while the high price points were addressed for 2024, including a significant drop in hotel rates. For 2025, officials in Las Vegas have brought forward the start time from its previous slot of 10 p.m. PT on Saturday to 8 p.m. after feedback from both paddock personnel and fans about it being too late to start the race. (Alex Bierensfor Heineken)
Forbes
21 minutes ago
- Forbes
The Chime IPO Will Kickstart A Fintech Investment Comeback
Chris Britt, co-founder and chief executive officer of Chime Financial Inc., during the company's ... More initial public offering at the Nasdaq MarketSite in New York, US, on Thursday, June 12, 2025. Chime launched its IPO with a splash. Shares jumped as much as 59% above the $27 offering price—opening at $43 and closing near $37—marking a bold public debut for the US's largest neobank. With a valuation hovering between $11.6 billion and $15 billion—well below its 2021 private peak of $25 billion—the surge raises the question: Will this trigger renewed investment in neobanks and fintech? Chime's IPO follows strong debuts from fintechs like Circle and eToro. PitchBook's Rudy Yang framed Chime as 'a strategic breakthrough—marking a return of fintech liquidity' after the sector saw VC exit values plummet from $222 billion in 2021 to under $30 billion in the past few years. Chime could be a bellwether for a neobank--and broader fintech--recovery if it: There is another side of the coin: Is Chime's IPO really a pivotal moment for the fintech industry and a validation of the digital-banking model and a template for future bank challengers? No. Chime's debut feels more like a secure base camp than a flag planted atop Everest. It suggests that public markets are open to credible fintech challengers—provided they bring scale, strong unit economics, and realistic valuations. The critical questions for neobanks: 1) Can they diversify revenue beyond interchange (loans, wealth, insurance)? 2) Will macro conditions hold stable enough to sustain IPO markets? 3) Will consumer-trust and customer growth trajectories support future public offerings? The answers are no. There are market factors impacting neobanks that have closed the door to new neobanks coming into the market: 1) Megafintechs have better economics and business models. Among consumers who consider a digital bank or neobank their primary checking account or payments provider, half of them say their primary provider is PayPal or Square Cash App. Neobanks don't just compete with incumbent banks—they compete with the megafintechs, whose platform business models give them scale and revenue diversity. 2) Interchange isn't a reliable revenue source. Relying on interchange runs against consumer behavior trends regarding: 3) The niche affinity play is tough for startups. This strategy requires neobanks to identify a segment's unique financial needs and Be the dominant affinity. Neobanks' claims of how big their affinity groups are misleading because most of us belong to multiple affinity groups. Fintech has entered a new phase—one defined by realism, consumer impact, and long-term value creation. The new phase, however, isn't about bank disruption and displacement--it's about banking industry infrastructure upgrade and replacement. The Chime IPO will help create more VC interest in fintech investment--but that investment won't go to new neobanks. Instead, it will go to startups that bring two things to the financial services industry: 1) AI-driven process reinvention from machine learning, Generative AI, and Agentic AI tools and technologies, and 2) Stablecoin and other cryptocurrency-related payments innovation. The latter may do more to disrupt banks than Chime and other neobanks have done.
Gizmodo
22 minutes ago
- Gizmodo
It's Not Free Yet, but This 15″ HP Laptop (Core i3, 2TB SSD, 64GB RAM) Is $2,300 Off on Amazon
When it comes to laptops, there's a model for every type of user – students, professionals and everyone in between. At the moment, Amazon is putting on an amazing sale on a model that meets all requirements: HP 15.6-inch touchscreen laptop (Intel Core i3, 2TB SSD, 64GB RAM) which is currently available at an all-time low price: This powerhouse of a machine (suited for any type of user) which normally costs $2,769, is now available for just $769 which is a 72% discount. This is one of our favorite laptop deals since the beginning of the year, and it matches previous deals seen during Black Friday. See at Amazon For less than $800, you get a machine running on Windows 11 Pro that would otherwise retail for several thousand and that is without considering the lifetime subscription for Microsoft Office Pro that is thrown in. You'll also get a free 7-in-1 USB-A adapter, a mouse, a mobile phone magnetic holder and a 128GB USB stick. Basically, you get $299 of accessories for free. Great Specs For a Laptop The HP 15.6 touchscreen notebook runs on a Intel i3-1315U processor that can run at speeds of up to 4.5 GHz, and is complemented by a massive 64GB of RAM and a 2TB SSD. These are some of the most robust specs of any Windows notebooks on the market and it's particularly suited for content creators, coders and anyone who requires multitasking. The 15.6-inch FHD touchscreen provides accurate and multi-finger gestures and smooth navigation for intuitive control and interaction with your work or entertainment in a natural manner (you don't have to use it if you're not a huge fan of touchscreens). The screen has a high-brightness backlight and high-contrast technology to provide true-to-life colors and clear visuals in any environment. This renders the laptop an ideal tool for mobile office use, creative work, or merely viewing high-definition media. You will also appreciate the audio part: The two speakers with specially tuned sound provide excellent stereo sound while Wi-Fi 6E and Bluetooth 5.3 provide ultra-stable and speedy wireless connectivity with less delay. These are especially useful for streaming, video calling, and online collaboration. For extra peace of mind, the laptop has a physical camera shutter and microphone mute button as well as an LED light to give users security reassurance. Make sure you grab yours before it runs out of stock. See at Amazon
